Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.43 |
| ▸ | CCNC | P24863 | 5/20 | 0.42 |
| ▸ | CDK8 | P49336 | 5/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | PASK | Q96RG2 | 1/20 | 0.36 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656506 | 0.93 | KDM1A (0.41) | KDM1ACCNCCDK8OPRD1CYP3A4 | |
| SCHEMBL5662346 | 0.91 | KDM1A (0.44) | KDM1ACCNCCDK8OPRD1CYP3A4 | |
| SCHEMBL5658735 | 0.89 | CCNC (0.45) | KDM1ACCNCCDK8OPRD1CYP3A4 | |
| SCHEMBL5661343 | 0.89 | KDM1A (0.41) | KDM1ACCNCCDK8OPRD1CYP3A4 | |
| SCHEMBL5659717 | 0.84 | CALCA (0.39) | — | |
| SCHEMBL5658225 | 0.84 | OPRD1 (0.44) | KDM1ACCNCCDK8OPRD1CYP3A4 | |
| SCHEMBL5657890 | 0.81 | CYP3A4 (0.58) | CYP3A4ROCK2CALCRL | |
| SCHEMBL5659896 | 0.79 | CALCRL (0.50) | OPRD1CYP3A4ROCK2DPP4CALCRL | |
| SCHEMBL5659612 | 0.78 | CYP3A4 (0.55) | CYP3A4ROCK2CALCRL | |
| SCHEMBL3278695 | 0.77 | DPP8 (0.42) | OPRD1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | claimed |
| US-7205294-B2 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-17 | — | — | US | disclosed |
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BDKRB1, BDKRB2, CALCRL | KDM1A 4125/4885CCNC 2475/4885CDK8 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.